Dubey P, Pathak D, Ali F, Chauhan G, Kalaiselvan V
Curr Drug Discov Technol. 2023; 21(2):e170723218813.
PMID: 37461340
DOI: 10.2174/1570163820666230717161610.
Aksenov D, Akulova A, Aleksandrova E, Aksenov N, Leontiev A, Aksenov A
Molecules. 2023; 28(5).
PMID: 36903571
PMC: 10005103.
DOI: 10.3390/molecules28052324.
Pei J, Chang W, Hsu P, Chen C, Yang Y, Hsu S
In Vivo. 2022; 36(4):1637-1642.
PMID: 35738638
PMC: 9301415.
DOI: 10.21873/invivo.12874.
Dahal A, Lo M, Singh S, Vo H, ElHage D, Jois S
Chem Biol Drug Des. 2022; 99(4):620-633.
PMID: 35156777
PMC: 10127554.
DOI: 10.1111/cbdd.14030.
Zhang J, Fan T, Mao Y, Hou J, Wang M, Zhang M
Nat Metab. 2021; 3(6):859-875.
PMID: 34140692
DOI: 10.1038/s42255-021-00405-8.
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.
Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T
Signal Transduct Target Ther. 2021; 6(1):201.
PMID: 34054126
PMC: 8165101.
DOI: 10.1038/s41392-021-00572-w.
Role of the base CsCO on the palladium-catalyzed intramolecular cyclization of two bromoindole derivatives to yield paullone-type products.
Velasquez C, Torres A, Gomez-Pech C, Avila-Zarraga J, Colmenares F
J Mol Model. 2021; 27(1):9.
PMID: 33392849
DOI: 10.1007/s00894-020-04638-4.
-Vanillin Derived Schiff Bases and Their Organotin(IV) Compounds: Synthesis, Structural Characterisation, In-Silico Studies and Cytotoxicity.
Yusof E, Latif M, Tahir M, Sakoff J, Simone M, Page A
Int J Mol Sci. 2019; 20(4).
PMID: 30781445
PMC: 6413231.
DOI: 10.3390/ijms20040854.
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors.
Premnath P, Craig S, McInnes C
J Vis Exp. 2015; (105):e52441.
PMID: 26554946
PMC: 4692680.
DOI: 10.3791/52441.
CDK5 knockdown prevents hippocampal degeneration and cognitive dysfunction produced by cerebral ischemia.
Gutierrez-Vargas J, Munera A, Cardona-Gomez G
J Cereb Blood Flow Metab. 2015; 35(12):1937-49.
PMID: 26104286
PMC: 4671113.
DOI: 10.1038/jcbfm.2015.150.
The immunopharmacologic potential of Semaxanib and new generation directed therapeutic drugs: Receptor tyrosine kinase regulation with anti-tumorigenensis/angiogenesis properties.
Haddad J
Saudi Pharm J. 2013; 20(2):103-23.
PMID: 23960782
PMC: 3744945.
DOI: 10.1016/j.jsps.2011.09.002.
High-throughput screening with the Eimeria tenella CDC2-related kinase2/cyclin complex EtCRK2/EtCYC3a.
Suarez Fernandez M, Engels K, Bender F, Gassel M, Marhofer R, Mottram J
Microbiology (Reading). 2012; 158(Pt 9):2262-2271.
PMID: 22723289
PMC: 3542813.
DOI: 10.1099/mic.0.059428-0.
Silencing of CDK5 reduces neurofibrillary tangles in transgenic alzheimer's mice.
Piedrahita D, Hernandez I, Lopez-Tobon A, Fedorov D, Obara B, Manjunath B
J Neurosci. 2010; 30(42):13966-76.
PMID: 20962218
PMC: 3003593.
DOI: 10.1523/JNEUROSCI.3637-10.2010.
Homology modeling, molecular dynamic simulation and docking studies of cyclin dependent kinase 1.
Zhang L, Zhu H, Wang Q, Fang H, Xu W, Li M
J Mol Model. 2010; 17(2):219-26.
PMID: 20419498
DOI: 10.1007/s00894-010-0710-z.
How to choose relevant multiple receptor conformations for virtual screening: a test case of Cdk2 and normal mode analysis.
Sperandio O, Mouawad L, Pinto E, Villoutreix B, Perahia D, Miteva M
Eur Biophys J. 2010; 39(9):1365-72.
PMID: 20237920
DOI: 10.1007/s00249-010-0592-0.
Marine pyrrolocarbazoles and analogues: synthesis and kinase inhibition.
Deslandes S, Chassaing S, Delfourne E
Mar Drugs. 2010; 7(4):754-86.
PMID: 20098609
PMC: 2810226.
DOI: 10.3390/md7040754.
Explaining the inhibition of cyclin-dependent kinase 5 by peptides derived from p25 with molecular dynamics simulations and MM-PBSA.
Tan V, Zhang B, Lim K, Tay T
J Mol Model. 2009; 16(1):1-8.
PMID: 19466465
DOI: 10.1007/s00894-009-0514-1.
Identifying tumor cell growth inhibitors by combinatorial chemistry and zebrafish assays.
Xiang J, Yang H, Che C, Zou H, Yang H, Wei Y
PLoS One. 2009; 4(2):e4361.
PMID: 19194508
PMC: 2633036.
DOI: 10.1371/journal.pone.0004361.
Proceedings of the 10th Asian Pacific Congress of Clinical Biochemistry in conjunction with the Australasian Association of Clinical Biochemists' 42nd Annual Scientific Conference.
Clin Biochem Rev. 2008; 25(Supplement):S18-S128.
PMID: 18392121
PMC: 1934963.
Functional flexibility of human cyclin-dependent kinase-2 and its evolutionary conservation.
Bartova I, Koca J, Otyepka M
Protein Sci. 2007; 17(1):22-33.
PMID: 18042686
PMC: 2144583.
DOI: 10.1110/ps.072951208.
